Literature DB >> 9236415

Intermittent claudication. A risk profile from The Framingham Heart Study.

J M Murabito1, R B D'Agostino, H Silbershatz, W F Wilson.   

Abstract

BACKGROUND: Intermittent claudication identifies persons at increased risk for death and disability. METHODS AND
RESULTS: Using 38-year follow-up data for the original cohort in the Framingham Heart Study, we developed an intermittent claudication risk profile. Intermittent claudication occurred in a total of 381 men and women. Age, sex, serum cholesterol, hypertension, cigarette smoking, diabetes, and coronary heart disease were associated with an increased risk for claudication and were included in the profile. A pooled logistic regression model was used to compute the probability of intermittent claudication for specified levels of risk factors.
CONCLUSIONS: The intermittent claudication risk profile allows physicians to identify high-risk individuals during a routine office visit and can be used to educate patients about modifiable risk factors, particularly smoking and blood pressure. Improved compliance with risk factor modification strategies may result in a beneficial impact on survival.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9236415     DOI: 10.1161/01.cir.96.1.44

Source DB:  PubMed          Journal:  Circulation        ISSN: 0009-7322            Impact factor:   29.690


  109 in total

1.  Rates of lower-extremity amputation and arterial reconstruction in the United States, 1979 to 1996.

Authors:  J Feinglass; J L Brown; A LoSasso; M W Sohn; L M Manheim; S J Shah; W H Pearce
Journal:  Am J Public Health       Date:  1999-08       Impact factor: 9.308

Review 2.  Pharmacological treatment of patients with peripheral arterial disease.

Authors:  Chin K Kim; Carsten M Schmalfuss; Richard S Schofield; David S Sheps
Journal:  Drugs       Date:  2003       Impact factor: 9.546

Review 3.  Peripheral and cerebral atherothrombosis and cardiovascular events in different vascular territories: insights from the Framingham Study.

Authors:  William B Kannel; Philip A Wolf
Journal:  Curr Atheroscler Rep       Date:  2006-07       Impact factor: 5.113

4.  Characteristics of peripheral arterial disease in Japanese type 2 diabetic patients.

Authors:  S Gorogawa; O Iida; M Ikeda; T Watarai; M Kubota; S Nanto; H Kaneto; Y Yamasaki
Journal:  Diabetologia       Date:  2006-04-06       Impact factor: 10.122

5.  Symptomatic peripheral arterial disease: the value of a validated questionnaire and a clinical decision rule.

Authors:  Bianca Lw Bendermacher; Joep Aw Teijink; Edith M Willigendael; Marie-Louise Bartelink; Harry R Büller; Ron Jg Peters; Jelis Boiten; Machteld Langenberg; Martin H Prins
Journal:  Br J Gen Pract       Date:  2006-12       Impact factor: 5.386

Review 6.  Intermittent claudication.

Authors:  Kevin Cassar
Journal:  BMJ       Date:  2006-11-11

Review 7.  Statin therapy in cardiovascular diseases other than atherosclerosis.

Authors:  Dominique Beaudry; Kenneth E Stone; Suzanne Wetherold; John Hemphill; Dat Do; John McClish; Robert Chilton
Journal:  Curr Atheroscler Rep       Date:  2007-01       Impact factor: 5.113

8.  The combination of 9p21.3 genotype and biomarker profile improves a peripheral artery disease risk prediction model.

Authors:  Kelly P Downing; Kevin T Nead; Yoko Kojima; Themistocles Assimes; Lars Maegdefessel; Thomas Quertermous; John P Cooke; Nicholas J Leeper
Journal:  Vasc Med       Date:  2013-12-09       Impact factor: 3.239

9.  Impact of hypertension history on short and long-term prognosis in patients with acute myocardial infarction treated with percutaneous angioplasty: comparison between STEMI and NSTEMI.

Authors:  Emanuele Cecchi; Maria Grazia D'Alfonso; Marco Chiostri; Elena Parigi; Daniele Landi; Serafina Valente; Salvatore Mario Romano; Gian Franco Gensini; Cristina Giglioli
Journal:  High Blood Press Cardiovasc Prev       Date:  2013-11-12

Review 10.  Oxidative stress as a mechanism of added sugar-induced cardiovascular disease.

Authors:  Kailash Prasad; Indu Dhar
Journal:  Int J Angiol       Date:  2014-12
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.